A Randomized, Blinded, Placebo-Controlled Study To Evaluate The Effect Fixed-Dose Leucine, Metformin, Sildenafil Combinations(NS-0200) Versus Placebo On Hepatic Fat Assessed By MRI In Non Alcoholic Fatty Liver Disease Patients

Trial Profile

A Randomized, Blinded, Placebo-Controlled Study To Evaluate The Effect Fixed-Dose Leucine, Metformin, Sildenafil Combinations(NS-0200) Versus Placebo On Hepatic Fat Assessed By MRI In Non Alcoholic Fatty Liver Disease Patients

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Leucine/metformin/sildenafil (Primary)
  • Indications Non-alcoholic fatty liver disease
  • Focus Therapeutic Use
  • Acronyms TRIPLN
  • Sponsors NuSirt Biopharma
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Mar 2017 Planned End Date changed from 1 Feb 2017 to 1 May 2017.
    • 13 Jan 2017 Planned End Date changed from 1 Jan 2017 to 1 Feb 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top